Fifth Lane Capital »

Inhibikase Therapeutics shares owned by Fifth Lane Capital

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Fifth Lane Capital from 13F filings

Historical chart of Fifth Lane Capital investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Fifth Lane Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Fifth Lane Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $42k 25k 1.68

More positions owned by Fifth Lane Capital

Renatus Tactical Acquis Shs Cl A (RTAC)
Onestream Cl A
Cantor Equity Partners V Shs Cl A S (CEPV)
Hologic
Cantor Equity Partners Ii In Cl A Ord Shs
New Amer Acquisition I Corp Unit 99/99/9999 (NWAX.U)
Electronic Arts (EA)
Arcellx Common Stock (ACLX)
Futurecrest Acquisition Corp Cl A Ord Shs (FCRS)
Listed Fds Tr Roundhill Magnif (MAGS)
New Amer Acquisition I Corp Com Shs Cl A (NWAX)
Futurecrest Acquisition Corp Unit 99/99/9999 (FCRS.U)
UnitedHealth (UNH)
Abivax Sa Sponsored Ads (ABVX)
Core Scientific (CORZ)

View all positions for Fifth Lane Capital

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Trails Edge Capital Partners
ADAR1 Capital Management
BlackRock
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Saturn V Capital Management
Kalehua Capital Management
Squadron Capital Management
Millennium Management
Nantahala Capital Management

View all funds holding Inhibikase Therapeutics